文献速递胰腺与胆道疾病消化内镜

单剂抗生素预防在原发性硬化性胆管炎择期胆管介入中的效果

Effect of a single-dose antibiotic prophylaxis in scheduled bile duct interventions in primary sclerosing cholangitis.
PubMed 文献 · Gastrointest Endosc · 2026-08-03

这项基于注册的非干预性队列研究比较了原发性硬化性胆管炎患者择期ERCP时单剂围介入抗生素预防(SOP队列,80例操作)与多日方案(历史队列,100例操作)的效果。结果显示两组术后胆管炎发生率无显著差异,但SOP队列中中重度胆管炎比例显著更高(45.5% vs 9.1%,P < .001),单因素分析发现传统主导性狭窄及ERCP中扩张是胆管炎显著危险因素。

要点

  • 单剂抗生素预防未增加PSC患者择期ERCP术后胆管炎发生率。
  • 但单剂方案组中重度胆管炎比例显著高于多日方案组。
  • 传统主导性狭窄及ERCP中扩张是术后胆管炎的显著危险因素。

核心结论

  • 在PSC患者择期ERCP中,单剂抗生素预防与多日方案相比未增加术后胆管炎发生率,但胆管炎严重程度更高,提示预防效果可能相当。

研究设计与样本

  • 基于注册的非干预性队列研究,比较新引入的围介入单剂预防标准操作流程(SOP队列,80例操作)与接受多日方案的历史队列(100例操作)。
  • 采用2018年东京指南进行胆管炎的诊断和严重程度分级。

主要发现

  • 围介入抗生素疗程中位数在SOP队列为0.33天,历史队列为3.50天(P < .001)。
  • 两组术后ERCP胆管炎发生率无显著差异,即使在行扩张的操作中亦如此。
  • 将胆管炎严重程度二分(I级 vs II+III级)后,SOP队列中中重度胆管炎比例显著更高(45.5% vs 9.1%;P < .001)。
  • 单因素分析显示,传统主导性狭窄(OR 3.360;P = .034)和ERCP中行扩张(OR 3.356;P = .033)是术后胆管炎的显著危险因素。

临床怎么用

  • 对于PSC患者择期ERCP,可考虑单剂抗生素预防以减少抗生素暴露,但需警惕中重度胆管炎风险。
  • 存在传统主导性狭窄或需行扩张的患者术后胆管炎风险较高,应加强监测。

局限性

  • 非干预性历史对照设计可能存在偏倚。
  • 样本量有限(SOP队列80例操作,历史队列100例操作)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The recommended duration of antibiotic prophylaxis in scheduled ERCP for patients with primary sclerosing cholangitis (PSC) varies greatly across international guidelines. Increasing antibiotic resistance makes the rational use of antibiotics urgently necessary. Therefore, we aimed to investigate the effect of an antibiotic single-dose prophylaxis on the rate of postinterventional cholangitis, the antibiotic exposure, and potential risk factors for cholangitis in this cohort. METHODS: A registry-based, noninterventional cohort study was conducted to investigate the effect of a newly introduced standard operating procedure (SOP) with a peri-interventional single-dose prophylaxis (SOP cohort, n = 80 procedures) compared with a historical cohort (n = 100 procedures) receiving a multiday regimen. Tokyo guidelines from 2018 were adapted for diagnosis and severity grading of cholangitis. RESULTS: The duration of the peri-interventional antibiotic therapy differed significantly between cohorts, with a median of 0.33 days in the SOP cohort and 3.50 days in the historical cohort (P < .001), whereas no significant difference in the rate of post-ERCP cholangitis between the cohorts was found, even in procedures with dilation. When cholangitis severity was dichotomized into grade I versus grade II + III, the SOP cohort showed a significantly higher proportion of moderate to severe cholangitis (45.5% vs 9.1%; P < .001). Identified significant risk factors (in univariate analysis) for a post-ERCP cholangitis were the presence of a traditional dominant stricture and the subsequent performance of dilation during ERCP (odds ratio [OR], 3.360; P = .034, and OR, 3.356; P = .033, respectively). CONCLUSIONS: In our study in patients with PSC, the antibiotic single-dose prophylaxis in scheduled ERCPs was not associated with a higher rate of postinterventional cholangitis, but with an increase in the cholangitis grade compared with a multiday regimen, indicating a potentially comparable effectiveness in preventing postinterventional cholangitis.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Seeßle J, Ruhberg L, Kirchner M, et al. Effect of a single-dose antibiotic prophylaxis in scheduled bile duct interventions in primary sclerosing cholangitis. Gastrointest Endosc. 2026. PMID: 42546782. doi:10.1016/j.gie.2026.07.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。